Frequently Asked Questions

No, 

EXtatin Inc. is a pioneering biotechnology research and development firm dedicated to advancing a revolutionary biological technology designed to expedite and enhance tattoo removal without causing scarring. Despite the passage of decades, the field of tattoo removal has seen minimal advancements. Concurrently, the desire for a safe, efficient, topical solution to address tattoo regrets has been exponentially increasing. At the forefront of tattoo removal research and development, EXtatin is leveraging over a decade of experience in this domain to tap into a multi-billion dollar market opportunity. Utilizing cutting-edge technologies and examining removal modalities in both human and animal models, EXtatin aims to eliminate tattoos through biological approaches. We posit that for tattoo removal to become appealing, the process must be accelerated, less painful, and yield more predictable outcomes.

EXtatin Inc. boasts a storied history marked by significant achievements in biotechnology research, with a leadership team comprising accomplished individuals, including the co-founders.

A notable milestone is the successful completion of Phase 1 within a 3-Phased pilot research project. Dr. Nik served as the Principal Investigator (PI) at the SUNNYBROOK RESEARCH INSTITUTE (SRI) during this phase. The study, conducted on live human tattooed skin, strictly adhered to bioethical standards set by the Institutional Review Board (IRB). The findings from this phase revealed promising signals that could potentially enhance the safety and efficiency of the tattoo removal process. The primary focus was on identifying a newly discovered side population and potential drug target within tattooed skin.

EXTATIN is actively building on this foundation as it advances in its quest for breakthroughs in biological technology for tattoo removal. Notably, the late Dr. Sheldon M. Joseph, Hons. B.S., Ph.D., played a pivotal role as both a co-founder and the site PI during the initiation of the Phase 1 study. Another co-founder, Frederick Hawa, is responsible for engaging with investors and fostering business relations, contributing to the continued success of EXtatin Inc.

In the United States alone, approximately 84 million people have tattoos, with an estimated 12 million to 20 million individuals expressing tattoo regrets (Economist, Dec 2016). European and OECD statistics align with those of the US, contributing to the potentially substantial market. Given the exponential increase in tattooing rates worldwide each year, we conservatively estimate the global market size of individuals experiencing tattoo regret to be around 50 million individuals. This sizable market underscores the demand for effective tattoo removal solutions.